Cingulate Inc. CING
are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM ("PTRTM") drug delivery
platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With
an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder ("ADHD") and anxiety, we are identifying and
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $9.8M | $9.4M | $15.5M | $9.0M | $8.4M | $5.1M | — |
| SG&A | $10.2M | $6.2M | $7.3M | $8.5M | $12.3M | $2.0M | — |
| Operating income | -$19.9M | -$15.6M | -$22.8M | -$17.5M | -$20.7M | -$7.1M | — |
| Interest expense | $1.4M | $99.2K | $790.0K | $292.3K | — | — | — |
| Pre-tax income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M | -$7.2M | — |
| Net income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M | -$7.2M | — |
| EPS, basic | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 | — | — |
| EPS, diluted | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 | — | — |
| Shares, diluted (wtd. avg.) | $5.1M | $1.5M | $75.4K | $602.3K | $7.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.0M | $12.2M | $52.4K | $5.4M | $16.5M | $1.2M | $418.5K |
| Short-term investments | — | — | — | — | $933 | $933 | — |
| Total current assets | $12.0M | $12.7M | $578.6K | $7.9M | $18.9M | $1.8M | — |
| Property, plant and equipment | $1.7M | $2.1M | $2.5M | $2.9M | $3.1M | $3.0M | — |
| Total assets | $15.1M | $14.9M | $3.5M | $11.4M | $22.9M | $5.8M | — |
| Accounts payable | $2.0M | $1.3M | $5.2M | $762.4K | $264.7K | $975.1K | — |
| Total current liabilities | $10.3M | $5.0M | $10.2M | $7.0M | $1.2M | $3.4M | — |
| Total liabilities | $12.6M | $7.4M | $10.4M | $7.5M | $2.0M | $4.5M | — |
| Retained earnings | -$132.4M | -$109.9M | -$92.9M | -$69.4M | -$51.7M | -$31.0M | — |
| Total equity | $2.5M | $7.5M | -$6.9M | $3.9M | $20.8M | $1.3M | $615.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.2M | -$18.5M | -$15.0M | -$15.9M | -$10.4M | -$6.8M | — |
| Depreciation and amortisation | $540.9K | $653.1K | $582.9K | $394.0K | $708.3K | $666.0K | — |
| Stock-based compensation | $1.5M | $995.5K | $812.7K | $800.8K | $43.8K | — | — |
| Capital expenditure | $162.1K | $211.8K | $224.1K | $153.4K | $814.7K | $402.1K | — |
| Investing cash flow | -$162.1K | -$211.8K | -$224.1K | -$152.7K | -$814.7K | -$384.2K | — |
| Financing cash flow | $16.1M | $30.8M | $10.0M | $4.9M | $26.5M | $8.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-010882.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |